

# Is hepcidin a possible contributor to impaired iron mobilization and anaemia in hepatitis C patients treated with pegylated interferon alpha and ribavirin therapy? A pilot study

ACTRN12611001188921

---

**Status** RECRUITING  
**Sponsor** Prof John Olynyk  
**Enrollment** 30 participants

## Plain Language Summary

---

This study looks at a blood protein called hepcidin in people with Hepatitis C who are being treated with interferon and ribavirin. These treatments often cause anaemia (low red blood cell counts) as a side effect. Researchers think hepcidin might be partly responsible because it blocks iron from being used to make new red blood cells. By measuring hepcidin levels in 30 patients during treatment, researchers hope to find out if hepcidin is a useful target to help prevent anaemia during Hepatitis C therapy.

You may be eligible if:

- You have a confirmed diagnosis of chronic Hepatitis C infection
- You are currently being treated with interferon alpha and ribavirin at Fremantle Hospital

You may NOT be eligible if:

- You are already participating in another clinical trial

Talk to your doctor about whether this trial might be right for you.

## Key Eligibility Criteria

---

### Inclusion (1)

- We will prospectively study 30 consecutive patients with Hepatitis C infection that are being treated with interferon alpha and ribavirin at Fremantle hospital.

### Exclusion (1)

- participation in other clinical trials.

## Locations (1 total)

---

Fremantle Hospital and Health Service - Fremantle, WA, Australia